CEO corner

Get to learn more about Erik Kinnman, our CEO

Interview with Dr James Garner, CEO of Kazia Therapeutics

XR-17 is Vivesto’s proprietary delivery platform

Vivesto published its Q2 report for 2023 on August 24, 2023, at 08.00 am CEST.

The Share

Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program

Annual Report 2022